1. Schumacher YO, Sahm D, Baumstark MW, Pottgiesser T. Reticulocytes in athletes: Longitudinal aspects and the influence of long- and short-term exercise. Drug Testing and Analysis. 2010 October;2(10):469-474.  

2. Pottgiesser T, Schumacher Y, Funke H, Rennert K, Baumstark M, Neunuebel K, Mosig S. Gene expression in the detection of autologous blood transfusion in sports--a pilot study. Vox Sang. 2009 May;96(4):333-336.  

3. Schmid A, Knoebber J, Vogt S, Konig D, Deibert P, Bultermann D, Heinrich L, Baumstark M, Berg A, Storch M. Lipid profiles of persons with paraplegia and tetraplegia: sex differences. J.Spinal Cord Med. 2008;31(3):285-289.  

4. Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, Baumstark M, Dickhuth H, Berg A. Frequency of secondary dyslipidemia in obese children. Vasc.Health Risk Manag. 2008;4(5):1089-1094.  

5. Bisse E, Schaeffer C, Hovasse A, Preisler-Adams S, Epting T, Baumstark M, Van Dorsselaer A, Horst J, Wieland H. Haemoglobin Noah Mehmet Oeztuerk (alpha(2) delta(2)143 (H21)His-->Tyr: A novel delta-chain variant in the 2,3-DPG binding site. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci. 2008;871(1):55-59.  

6. Lunin V, Lunina N, Baumstark M. Estimates of the twinning fraction for macromolecular crystals using statistical models accounting for experimental errors. Acta Crystallogr.D Biol.Crystallogr. 2007 November;63(Pt 11):1129-1138.  

7. Bisse E, Zorn N, Boussert S, Epting T, Van Dorsselaer A, Horst J, Baumstark M, Wieland H. Characterization of hemoglobin Wurzburg (alpha2beta2 4(A1)Thr-->Asn), a new electrophoretically silent variant, by mass spectrometry and molecular modeling studies. J.Chromatogr.A. 2006 May 19;1115(1-2):118-124.  

8. Storch M, Konig D, Bultermann D, Blum A, Vogt S, Baumstark M, Berg A, Schmid A. Lipid profile in spinal cord-injured women with different injury levels. Prev.Med. 2005 March;40(3):321-325.  

9. ISS Program Scientist Office. NASA - Advanced Protein Crystallization Facility - Crystallization of Human Low Density Lipoprotein (LDL) Subfractions in Microgravity (APCF-Lipoprotein). [Internet]. 2005 [cited 2010 October 28]. Available from: http://www.nasa.gov/mission_pages/station/research/experiments/APCF-Lipoprotein.html

10. Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell H, Hauck P, Hoffmann M, Baumstark M, Wieland H, Marz W. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp.Clin.Endocrinol.Diabetes. 2004 May;112(5):241-247.  

11. Scharnagl H, Winkler K, Mantz S, Baumstark M, Wieland H, Marz W. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. Exp.Clin.Endocrinol.Diabetes. 2004 May;112(5):269-277.  

12. Schmidt-Trucksass A, Baumstark M, Daub C, Espenschied S, Grathwohl D, Berg A. Lipoprotein phenotype and adhesion molecules correlate with diurnal triglyceride profiles in patients with coronary artery disease. Nutr.Metab Cardiovasc.Dis. 2004 February;14(1):20-25.  

13. Wetzka B, Hoffmann M, Friedrich I, Baumstark M, Zahradnik H, Marz W, Winkler K. Transient remnant removal disease in acute fatty liver of pregnancy. Hypertens.Pregnancy. 2004;23(2):143-153.  

14. Konig D, Vaisanen S, Bouchard C, Halle M, Lakka T, Baumstark M, Alen M, Berg A, Rauramaa R. Cardiorespiratory fitness modifies the association between dietary fat intake and plasma fatty acids. Eur.J.Clin.Nutr. 2003 July;57(7):810-815.  

15. Winkler K, Wetzka B, Hoffmann M, Friedrich I, Kinner M, Baumstark M, Zahradnik H, Wieland H, Marz W. Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. Journal of Clinical Endocrinology & Metabolism. 2003 March;88(3):1162-1166.  

16. Schmidt-Trucksass A, Sandrock M, Cheng DC, Muller H, Baumstark M, Rauramaa R, Berg A, Huonker M. Quantitative measurement of carotid intima-media roughness-effect of age and manifest coronary artery disease. Atherosclerosis. 2003 January;166(1):57-65.  

17. Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark M, Krebs K, Wieland H, Marz W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003;26(9):2588-2594.  

18. Berg A, Konig D, Deibert P, Grathwohl D, Berg A, Baumstark M, Franz I. Effect of an oat bran enriched diet on the atherogenic lipid profile in patients with an increased coronary heart disease risk. A controlled randomized lifestyle intervention study. Ann.Nutr.Metab. 2003;47(6):306-311.  

19. Winkler K, Abletshauser C, Hoffmann M, Friedrich I, Baumstark M, Wieland H, Marz W. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. Journal of Clinical Endocrinology & Metabolism. 2002 December;87(12):5485-5490.  

20. Wiemer J, Winkler K, Baumstark M, Marz W, Scherberich J. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol.Dial.Transplant. 2002 December;17(12):2231-2238.  

21. Marz W, Scharnagl H, Abletshauser C, Hoffmann M, Berg A, Keul J, Wieland H, Baumstark M. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation. 2001 April 17;103(15):1942-1948.  

22. Lunin V, Lunina N, Ritter S, Frey I, Berg A, Diederichs K, Podjarny A, Urzhumtsev A, Baumstark M. Low-resolution data analysis for low-density lipoprotein particle. Acta Crystallographica. 2001 January;D57:108-121.  

23. Winkler K, Wetzka B, Hoffmann M, Friedrich I, Kinner M, Baumstark M, Wieland H, Marz W, Zahradnik H. Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. Journal of Clinical Endocrinology & Metabolism. 2000 December;85(12):4543-4550.  

24. Pedersen A, Baumstark M, Marckmann P, Gylling H, Sandström B. An olive oil-rich diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles than rapeseed oil and sunflower oil diets. J.Lipid Res. 2000 December;41(12):1901-1911.  

25. Schmid A, Halle M, Stutzle C, Konig D, Baumstark M, Storch M, Schmidt-Trucksass A, Lehmann M, Berg A, Keul J. Lipoproteins and free plasma catecholamines in spinal cord injured men with different injury levels. Clin.Physiol. 2000 July;20(4):304-310.  

26. Hoffmann M, Wolfarth B, Schlemmer E, Wieland H, Marz W, Baumstark M. Genetische Varianten der Lipoprotein Lipase und der Hepatischen Triglycerid Lipase und ihr Einfluß auf die Low Density und High Density Lipoprotein Subfraktionen. Manuskript Blaubeuren. 2000.  

27. Halle M, Berg A, Baumstark M, Keul J. Association of physical fitness with LDL and HDL subfractions in young healthy men. Int.J.Sports Med. 1999 October;20(7):464-469.  

28. Halle M, Berg A, Garwers U, Baumstark M, Knisel W, Grathwohl D, Konig D, Keul J. Influence of 4 weeks' intervention by exercise and diet on low-density lipoprotein subfractions in obese men with type 2 diabetes. Metabolism. 1999 May;48(5):641-644.  

29. Halle M, Berg A, Baumstark M, Konig D, Huonker M, Keul J. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels. Atherosclerosis. 1999 March;143(1):185-192.  

30. Ritter S, Diederichs K, Frey I, Berg A, Keul J, Baumstark M. Crystallization of human low density lipoprotein (LDL), a large lipid-protein complex - collection of X-ray data at very low resolution. J.Cryst.Growth. 1999;196:344-349.  

31. Halle M, Berg A, Baumstark M, Keul J. [LDL subfractions and coronary heart disease--an overview]. Z.Kardiol. 1998 May;87(5):317-330.  

32. Zulewski H, Ninnis R, Miserez A, Baumstark M, Keller U. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100. J.Lipid Res. 1998 February;39(2):380-387.  

33. Vaisanen S, Baumstark M, Penttila I, Bouchard C, Halonen P, Rankinen T, Berg A, Rauramaa R. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb.Haemost. 1997 December;78(6):1495-1499.  

34. Kramer-Guth A, Quaschning T, Pavenstadt H, Galle J, Nauck M, Baumstark M, Schollmeyer P, Marz W, Wanner C. Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells. Nephrol.Dial.Transplant. 1997 July;12(7):1336-1343.  

35. Ritter S, Frey I, Diederichs K, Grathwohl D, Keul J, Baumstark M. Crystallization and preliminary X-ray diffraction data of two different human low-density lipoprotein (LDL) subfractions. Proteins. 1997 June;28(2):293-297.  

36. Kramer-Guth A, Quaschning T, Galle J, Baumstark M, Koniger M, Nauck M, Schollmeyer P, Marz W, Wanner C. Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur.J.Clin.Invest. 1997 June;27(6):460-468.  

37. Halle M, Konig D, Berg A, Keul J, Baumstark M. Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis. 1997 February 10;128(2):235-240.  

38. Schaefer J, Scharnagl H, Baumstark M, Schweer H, Zech L, Seyberth H, Winkler K, Steinmetz A, Marz W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler.Thromb.Vasc.Biol. 1997 February;17(2):348-353.  

39. Halle M, Berg A, Konig D, Keul J, Baumstark M. Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men. Metabolism. 1997 February;46(2):186-191.  

40. Konig D, Berg A, Baumstark M, Halle M, Kothe K, Keul J. Effect of low dose fish oil supplementation on atherogenic parameters in patients with coronary heart disease and dyslipoproteinemia. Perfusion. 1997;10:48-54.  

41. Berg A, Halle M, Baumstark M, Keul J, Northoff H. Spontaneously low LDL cholesterol and reaction to exercise-induced stress. Lancet. 1996 February 10;347(8998):405.  

42. Halle M, Berg A, Keul J, Baumstark M. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler.Thromb.Vasc.Biol. 1996 January;16(1):144-148.  

43. Halle M, Berg A, von Stein T, Baumstark M, Konig D, Keul J. Lipoprotein(a) in endurance athletes, power athletes, and sedentary controls. Med.Sci.Sports Exerc. 1996;28(8):962-966.  

44. Halle M, Berg A, Frey I, Konig D, Keul J, Baumstark M. Relationship between obesity and concentration and composition of low-density lipoprotein subfractions in normoinsulinemic men. Metabolism. 1995 November;44(11):1384-1390.  

45. Berg A, Baumstark M, Halle M, Frey I, Keul J. Benefits of physical exercise in the prevention and treatment of dyslipoproteinemias. In: Jaross W, Hanefeld M, Bergmann S, editors. Advances in lipoprotein and artherosclerosis research, diagnostic and treatment. Jena: Gustav Fischer; 1995. pp. 108-112.  

46. Baumstark M. Low-Density-Lipoprotein Unterfraktionen und Schweregrad der koronaren Herzkrankheit: Untersuchungen an einem koronarangiographisch definierten Kollektiv. Herz & Gesundheit. 1995;14(2):19-20.  

47. Durovic S, Mrz W, Frank S, Scharnagl H, Baumstark M, Zechner R, Kostner G. Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500-->Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins. Journal of Biological Chemistry. 1994 December 2;269(48):30320-30325.  

48. Berg A, Frey I, Baumstark M, Halle M, Keul J. Physical activity and lipoprotein lipid disorders. Sports Med. 1994 January;17(1):6-21.  

49. Berg A, Halle M, Baumstark M, Keul J. Bedeutung der Lipoproteine bei der Pathogenese der KHK. Deutsches Arzteblatt. 1994;91:822-830.  

50. Marz W, Baumstark M, Scharnagl H, Ruzicka V, Buxbaum S, Herwig J, Pohl T, Russ A, Schaaf L, Berg A, et al. Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J.Clin.Invest. 1993 December;92:2922-2933.  

51. Flegel W, Baumstark M, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect.Immun. 1993 December;61(12):5140-5146.  

52. Northoff H, Baumstark M, Flegel W, Berg A. Systemic cytokine response to strenuous exercise. In: Faist M, editor. Host defense dysfunction in trauma, shock and sepsis. Berlin Heidelberg: Springer; 1993. pp. 720-724.  

53. Halle M, Berg A, Baumstark M. Differences in the concentration and composition of low-density lipoprotein subfraction particles in hypercholsterolemic men with and without hypertriglyceridemia. Nutr.Metab.Cardiovasc.Dis. 1993;3:179-184.  

54. Frey I, Baumstark M, Berg A. Acute and delayed effects of prolonged exercise on serum lipoproteins. I. Composition and distribution of high density lipoprotein subfractions. Eur.J.Appl.Physiol Occup.Physiol. 1993;66(6):521-525.  

55. Berg A, Frey I, Baumstark M, Halle M, Keul J. Sport und Lipide. LIPID aktuell. 1993;6:1-9.  

56. Baumstark M, Frey I, Berg A. Acute and delayed effects of prolonged exercise on serum lipoproteins. II. Concentration and composition of low-density lipoprotein subfractions and very low-density lipoproteins. Eur.J.Appl.Physiol Occup.Physiol. 1993;66(6):526-530.  

57. Frey I, Kamps H, Baumstark M, Berg A, Keul J. Distribution of lipoprotein species (LpA-I, LpA-I:A-II) in serum and HDL subfractions of untrained and trained normolipemic men. Clinica Chimica Acta. 1992 October 30;211(3):167-173.  

58. Baumstark M, Frey I, Berg A, Keul J. Influence of n-3 fatty acids from fish oils on concentration of high- and low-density lipoprotein subfractions and their lipid and apolipoprotein composition. Clin.Biochem. 1992 October;25(5):338-340.  

59. Baumstark M, Aristegui R, Zoller T, Frey I, Berg A, Keul J. Probucol, incorporated into LDL particles in vivo, inhibits generation of lipid peroxides more effectively than endogenous antioxidants alone. Clin.Biochem. 1992 October;25(5):395-397.  

60. Weinstock C, Ullrich H, Hohe R, Berg A, Baumstark M, Frey I, Northoff H, Flegel W. Low density lipoproteins inhibit endotoxin activation of monocytes. Arterioscler.Thromb. 1992 March;12(3):341-347.  

61. Berg A, Halle M, Baumstark M, Frey I, Keul J. Physical acivity, lipids, and lipoprotein metabolism: The benefit of exercise and training in hyperlipidemia. In: Watson R, Eisinger M, editors. Exercise and disease. CRC Press; 1992. pp. 25-36. Available from: file://X:\USER\miriam\projekte\pdf-archiv\2156.pdf  

62. Baumstark M, Arístegui R, Zöller T, Frey I, Berg A, Keul J. Probucol, in vivo incorporated into LDL particles, effectively inhibits generation of lipid peroxides. In: Halpern M, editor. Molecular Biology of Atherosclerosis. London: John Libbey & Co.; 1992. pp. 101-103.  

63. Baumstark M, von Stein T, Jakob E, Luley C, Berg A, Keul J. Testosterone lowers serum concentrations of lipoprotein Lp(a). In: Steinmetz A, Schneider J, Kaffarnik H, editors. Hormones in Lipoprotein Metabolism. Recent Developments in Lipid and Lipoprotein Research. Berlin: Springer-Verlag; 1992. pp. 165-168.  

64. Baumstark M, Arístegui R, Frey I, Berg A. Probucol, in vivo incorporated into LDL particles, effectively inhibits generation of lipid peroxides. In: Gotto A, Mancini M, Richter W, Schwandt P, editors. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease. Vol. 3. München: Krager; 1992.  

65. Baumstark M, Halle M, Frey I, Berg A, Keul J. Influence of n-3 fatty acids on composition and concentration of lipoprotein subfractions. In: Halpern M, editor. Molecular Biology of Atherosclerosis. London: John Libbey & Co.; 1992. pp. 187-190.  

66. Luley C, Baumstark M, Wieland H. Rapid apolipoprotein E phenotyping by immunofixation in agarose. J.Lipid Res. 1991 May;32(5):880-883.  

67. Frey I, Baumstark M, Berg A, Keul J. Influence of acute maximal exercise on lecithin:cholesterol acyltransferase activity in healthy adults of differing aerobic performance. Eur.J.Appl.Physiol Occup.Physiol. 1991;62(1):31-35.  

68. Berg A, Baumstark M, Frey I, Halle M, Keul J. Clinical and therapeutic use of probucol. Eur.J.Clin.Pharmacol. 1991;40 Suppl 1:S81-S84.  

69. Baumstark M, Kreutz W, Berg A, Keul J. Symmetry of the surface, and structure of the central core of human LDL particles, analyzed by X-ray small angle scattering. Adv.Exp.Med.Biol. 1991;285:123-130.  

70. Baumstark M, Halle M, Frey I, Berg A, Keul J. Aktuelle Aspekte zum Einfluß der körperlichen Aktivität auf den Lipid- und Lipoproteinstoffwechsel. Österreichisches Journal für Sportmedizin. 1991;21:100-104.  

71. Baumstark M, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochim.Biophys.Acta. 1990 January 19;1037(1):48-57.  

72. Northoff H, Flegel W, Mannel D, Baumstark M, Berg A. Increased levels of Interleukin-6 (IL-6) and /or IL-7 in sera of long-distance runners. In: The physiological and pathological effects of cytokines. Wiley-Liss, Inc.; 1990. pp. 75-79.  

73. Frey I, Berg A, Baumstark M, Collatz K, Keul J. Effects of age and physical performance capacity on distribution and composition of high-density lipoprotein subfractions in men. Eur.J.Appl.Physiol Occup.Physiol. 1990;60(6):441-444.  

74. Berg A, Baumstark M, Halle M, Frey I, Keul J. Welche Interaktionen, welche Effekte? Therapiewoche. 1990;40:2315-2325.  

...